Literature DB >> 16222535

Clinical significance of serum levels of soluble intercellular adhesion molecule-1 and soluble L-selectin in malignant melanoma.

Mizuki Yamada1, Koichi Yanaba, Kazuhiko Takehara, Shinichi Sato.   

Abstract

Although several molecules have been evaluated as tumor markers of malignant melanoma (MM) progression, there are few available markers sensitive enough to detect recurrence or metastasis. The objective of the present study was to determine clinical significance of serum soluble adhesion molecules in the monitoring of progression in patients with MM. Serum levels of soluble L-selectin (sL-selectin), sE-selectin, sP-selectin, and soluble intercellular adhesion molecule-1 (sICAM-1) were determined by ELISA in 57 MM patients. In a retrospective longitudinal study, nine serum samples from two MM patients were analyzed during a follow-up period of 4.0 and 4.3 years, respectively. Serum sICAM-1 levels in MM patients were significantly higher than those in healthy controls and tended to be elevated as the disease stage progressed. In contrast, serum sL-selectin levels were significantly lower in MM patients compared to healthy controls and tended to decrease as the disease stage progressed. There was no significant difference in serum sE-selectin and sP-selectin levels between MM patients and normal control. In a longitudinal study, increased sICAM-1 and decreased sL-selectin levels were generally associated with the progression of MM. These results suggest that monitoring both sICAM-1 and sL-selectin is available to evaluate the progression of MM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222535     DOI: 10.1007/s00403-005-0605-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  7 in total

1.  Plasma markers for identifying patients with metastatic melanoma.

Authors:  Harriet M Kluger; Kathleen Hoyt; Antonella Bacchiocchi; Tina Mayer; Jonathan Kirsch; Yuval Kluger; Mario Sznol; Stephan Ariyan; Annette Molinaro; Ruth Halaban
Journal:  Clin Cancer Res       Date:  2011-04-12       Impact factor: 12.531

2.  Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling.

Authors:  Sheng Pan; Ru Chen; David A Crispin; Damon May; Tyler Stevens; Martin W McIntosh; Mary P Bronner; Argyrios Ziogas; Hoda Anton-Culver; Teresa A Brentnall
Journal:  J Proteome Res       Date:  2011-03-28       Impact factor: 4.466

3.  Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.

Authors:  Gough G Au; Leone G Beagley; Erin S Haley; Richard D Barry; Darren R Shafren
Journal:  Virol J       Date:  2011-01-18       Impact factor: 4.099

Review 4.  Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies.

Authors:  Jochen Utikal; Dirk Schadendorf; Selma Ugurel
Journal:  Arch Dermatol Res       Date:  2007-03       Impact factor: 3.017

5.  The attenuation effect of low piperine Piper nigrum extract on doxorubicin-induced toxicity of blood chemical and immunological properties in mammary tumour rats.

Authors:  Jirakrit Saetang; Aman Tedasen; Surasak Sangkhathat; Natnaree Sangkaew; Sirinapa Dokduang; Napat Prompat; Siriporn Taraporn; Potchanapond Graidist
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

6.  LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro.

Authors:  Stephanie Ghislin; Dorian Obino; Sandrine Middendorp; Nicole Boggetto; Catherine Alcaide-Loridan; Frederique Deshayes
Journal:  BMC Cancer       Date:  2012-10-05       Impact factor: 4.430

7.  Incidence and metastasis of cutaneous malignant melanoma with respect to ABO blood groups: a case-controlled study in northeast of China.

Authors:  Liang Chang; Junrui Pei; Chenlong Li; Ping Zhang; Dan Zhou; Wenzhong Du; Xing Liu; Chuanlu Jiang
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.